Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEUS, CEDM, and CEMR for Early Detection of Breast Cancer
NCT03954015Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Oct 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sulfur hexafluoride in breast cancer, sponsored by Mayo Clinic. Primary endpoints: Contrast Enhanced Ultrasound True Positive Diagnosis at 1 year, Contrast Enhanced Ultrasound False Positive Diagnosis at 1 year and 2 more. Started Oct 2019; status: completed.
02
Drugs
sulfur hexafluoride
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03954015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03954015.